PF-04455242
| PF-04455242 | |
|---|---|
| PF-4455242.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 956905-27-4 |
| PubChem | 16005106 |
| DrugBank | |
| ChemSpider | 13180813 |
| KEGG | D09992 |
PF-04455242 is an investigational drug that was developed by Pfizer for the treatment of cognitive disorders such as schizophrenia and Alzheimer's disease. It acts as a selective dopamine receptor D1 antagonist.
Pharmacology[edit]
PF-04455242 is designed to target the dopamine receptor D1, which is implicated in various neurological disorders. By antagonizing this receptor, PF-04455242 aims to modulate the dopaminergic system, potentially improving cognitive function in patients with disorders like schizophrenia and Alzheimer's disease.
Mechanism of Action[edit]
The drug functions by selectively binding to the D1 subtype of dopamine receptors, inhibiting their activity. This action is thought to help in balancing the dopaminergic activity in the brain, which is often disrupted in cognitive disorders. The modulation of D1 receptors is believed to enhance working memory and executive function, which are typically impaired in these conditions.
Development and Research[edit]
PF-04455242 has undergone various stages of clinical trials to assess its efficacy and safety. Initial studies focused on its potential benefits in improving cognitive deficits associated with schizophrenia. However, the development of PF-04455242 has faced challenges, including the complexity of targeting specific dopamine receptors without affecting others, which can lead to side effects.
Potential Applications[edit]
The primary focus of PF-04455242 is on cognitive enhancement in disorders like schizophrenia and Alzheimer's disease. By improving cognitive functions, the drug could potentially enhance the quality of life for patients suffering from these debilitating conditions. However, further research is needed to fully understand its efficacy and safety profile.
Challenges and Considerations[edit]
Developing drugs that target the dopaminergic system is challenging due to the intricate balance required to avoid side effects. The specificity of PF-04455242 for the D1 receptor is crucial in minimizing unwanted interactions with other dopamine receptors, which could lead to adverse effects.
Related pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
